Costs associated with management of cervical human papillomavirus-related conditions

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 9, 2012, Pages 1469-1478

  Kruzikas, Denise ^a   Smith, Jennifer S ^b   Harley, Carolyn ^c   Buzinec, Paul ^c  

^a GLAXOSMITHKLINE   (United States)

^b IL   (United States)

^c OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BILLING AND CLAIMS; CANCER IMMUNIZATION; CHILD; COLPOSCOPY; CONTROLLED STUDY; CURETTAGE; DIAGNOSTIC PROCEDURE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYSTERECTOMY; INFANT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PAPILLOMAVIRUS INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; UTERINE CERVIX CANCER; WART VIRUS;

ADOLESCENT; ADULT; CERVIX UTERI; CHILD; CHILD, PRESCHOOL; DILATATION AND CURETTAGE; DNA, VIRAL; FEMALE; HEALTH CARE COSTS; HUMANS; HYSTERECTOMY; INFANT; INFANT, NEWBORN; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; VAGINAL SMEARS;

EID: 84866170622     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-1019     Document Type: Article

References (38)

1. The Centers for Disease Control and Prevention (CDC) Division of STD Prevention. Genital HPV infection. CDC fact sheet. 2008 [cited 2010 Dec 16]. Available from: http://www.cdc.gov/STD/HPV/STDFact-HPV.htm#common.
2. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA 2007;297:813-9.
3. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
4. American Social Health Association. National HPV and cervical cancer prevention resource center. 2011. [cited 2011 Oct 18]. Available from: http://www.ashastd.org/hpv/hpv-learn-fastfacts.cfm.
5. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al.Proyecto Epidemiológico Guanacaste Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-7.
6. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papillomavirus Cohort Study. Cancer Res 2008;68:8813-24.
7. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al.International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
8. Muñoz N, Bosch FX, Castellsagué X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
9. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
10. Koshiol JE, Lindsay L, Pimenta JM, Poole CL, Jenkins D, Smith JS. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008;168:123-37.
11. Jenkins M, Chiriva-Internati M, Mirandola L, Tonroy C, Tedjarati SS, Davis N, et al. Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol 2012;31:3-21.
12. American Cancer Society. Cancer facts & figures, 2010. Atlanta, GA: American Cancer Society; 2010.
13. American College of Obstetricians and Gynecologists. Practice Bulletin No. 66: Management of abnormal cervical cytology and histology. Washington, DC: ACOG; Sep 20, 2005.
14. Fleurence RL, Dixon JM, Milanova TF, Beusterien KM. Review of the economic and quality-of-life burden of cervical human papillomavirus disease. Am J Obstet Gynecol 2007;196:206-12.
15. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health 2004;36:11-9.
16. Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107-22.
17. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20.
18. Kreimer AR, Guido RS, Solomon D, Shiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006;15:908-14.
19. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Females united to unilaterally reduce endo/ectocervical disease (FUTURE) I investigators: quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
20. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
21. Ault KA FUTURE II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
22. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. HPV Vaccine Study Group: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-55.
23. FDA Approves Cervarix. Press release. 2011. [cited 2011 Oct 18]. Drugs.com. Available from: http://www.drugs.com/newdrugs/fda-approves-cervarix- glaxosmithkline-s-cervical-cancer-vaccine-1690.html.
24. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type-distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
25. The FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:3493.
26. The FUTURE II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
27. Romanowski B. Long term protection against cervical infection with the human papillomavirus: review of currently available vaccines. Hum Vaccin 2011;7:161-9.
28. Henk HJ, Insinga RP, Singhal PK, Darkow T. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010;14:29-36.
29. Wang NC, Laud PW, Macias M, Nattinger AB. Utility of a combined current procedural terminology and International Classification of Diseases, Ninth Revision, Clinical Modification code algorithm in classifying cervical spine surgery for degenerative changes. Spine 2011;36:1843-8.
30. Halpern R, Barghout V, Zarotsky V, Williams D. Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal tumors. J Clin Outcomes Manag 2009;16:215-23.
31. Schabert VF, Ye X, Insinga RP, Singhal PK, Riedel AA. Five-year routine cervical cancer screening rates and intervals in a US health plan. Curr Med Res Opin 2008;24:2429-35.
32. ACOG Committee on Practice Bulletins - Gynecology. ACOG Practice Bulletin no. 109: cervical cytology screening. Obstet Gynecol 2009;114:1409-20.
33. Subramanya D, Grivas PD. HPV and cervical cancer: updates on an established relationship. Postgrad Med 2008;120:7-13.
34. ACOG Committee on Gynecologic Practice. ACOG Committee Opinion No. 356: routine cancer screening. Obstet Gynecol 2006;108:1611-3.
35. Julius JM, Ramondeta L, Tipton KA, Lal LS, Schneider K, Smith JA. Clinical perspectives on the role of the human papillomavirus vaccine in the prevention of cancer. Pharmacotherapy 2011;31:280-97.
36. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008;359:821-32.
37. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003;290:781-9.
38. U.S. Preventive Services Task Force. Screening for cervical cancer. 2012. Available from: http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv. htm (last accessed June 4, 2012).